[go: up one dir, main page]

AR127706A1 - Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona - Google Patents

Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona

Info

Publication number
AR127706A1
AR127706A1 ARP220103168A ARP220103168A AR127706A1 AR 127706 A1 AR127706 A1 AR 127706A1 AR P220103168 A ARP220103168 A AR P220103168A AR P220103168 A ARP220103168 A AR P220103168A AR 127706 A1 AR127706 A1 AR 127706A1
Authority
AR
Argentina
Prior art keywords
spiro
furo
inden
piperidin
oxazole
Prior art date
Application number
ARP220103168A
Other languages
English (en)
Inventor
Jean Adam
- Bachmann Stephan Michel
Raphael Bigler
Pascal Dott
Serena Mara Fantasia
Katja Grosse-Sender
Philippe James
Paul Spurr
Juergen Thun
Sandro Tonazzi
Paolo Tosatti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR127706A1 publication Critical patent/AR127706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona procesos para elaborar 2’-(7,7-dimetil-1’H,7H-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’H-espiro[inden-2,5’-[1,3]oxazol]-4’-ona sustituida. También se divulgan compuestos útiles como intermediarios en los métodos de la invención. Reivindicación 1: Una forma cristalina de un compuesto de fórmula (I). Reivindicación 2: La forma cristalina A del compuesto de fórmula (I) de acuerdo con la reivindicación 1, caracterizada por un patrón de difracción de rayos X de polvo que tiene los picos característicos expresados en valores de grados 2-q a aproximadamente (± 0,20 grado 2-q). @@@@@@@@@
ARP220103168A 2021-11-19 2022-11-17 Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona AR127706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21209197 2021-11-19

Publications (1)

Publication Number Publication Date
AR127706A1 true AR127706A1 (es) 2024-02-21

Family

ID=78709265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103168A AR127706A1 (es) 2021-11-19 2022-11-17 Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona

Country Status (7)

Country Link
US (1) US20240309013A1 (es)
EP (1) EP4433482A1 (es)
JP (1) JP2024538400A (es)
CN (1) CN118251396A (es)
AR (1) AR127706A1 (es)
TW (1) TW202334162A (es)
WO (1) WO2023088996A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI531571B (zh) * 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
JPWO2013176220A1 (ja) 2012-05-25 2016-01-14 国立大学法人京都大学 概日リズム調整
HRP20180160T1 (hr) 2013-12-19 2018-02-23 F. Hoffmann - La Roche Ag Spiro-oksazoloni

Also Published As

Publication number Publication date
JP2024538400A (ja) 2024-10-18
WO2023088996A1 (en) 2023-05-25
TW202334162A (zh) 2023-09-01
US20240309013A1 (en) 2024-09-19
CN118251396A (zh) 2024-06-25
EP4433482A1 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
CR20190373A (es) DERIVADOS DE PIRROLO[1,2b]PIRIDAZINA
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
ECSP099818A (es) Procesos para la preparacion de pirazoles
MX2010001609A (es) Proceso para producir derivados de piripiropeno e intermediarios para la produccion de los mismos.
MX2018014871A (es) Proceso de preparacion de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4, 5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida .
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
FI3978483T3 (fi) (S)-afoksolaneerin kiteinen tolueenisolvaatti
NZ734535A (en) Process of producing cycloalkylcarboxamido-indole compounds
AR075368A1 (es) Inhibidores de glicosilceramida sintasa
CY1115866T1 (el) Τριαζολοπυριμιδινες
ES2618939T3 (es) Sal de camsilato
PE20210002A1 (es) Sales de derivados de pirrolotriazina utiles como inhibidores tam
AR047088A1 (es) Polimorfo cristalino de piridinetilennaftofurano como antagonista del receptor de trombina, metodo de obtencion y composiciones farmaceuticas
AR071246A1 (es) Proceso para la preparacion de compuestos utiles como inhibidores de sglt
CR20110427A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
AR064760A1 (es) Derivados de diazol como inhibidores de la eg-5
MX394421B (es) Derivados de piridona policiclica sustituida y profarmaco de los mismos
ECSP099441A (es) Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
PE20221340A1 (es) Compuestos heterociclicos
CO6241119A2 (es) Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
AR105091A1 (es) Procedimiento para la síntesis de derivados de rapamicina
PE20221732A1 (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
PH12013501140A1 (en) Photochromic compounds, compositions and articles
PE20050769A1 (es) Formas polimorficas de un agonista de gabaa
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.

Legal Events

Date Code Title Description
FB Suspension of granting procedure